Physician profile
Patrick G Devlin
NPI 1558360479
$1,170.30
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $536 · 2020: $195 · 2021: $294 · 2022: $145.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $269.99 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $202.83 | 2019-2021 | |
| Abbott Laboratories | $172.53 | 2021 | |
| Medtronic, INC. | $117.44 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $80.04 | 2020-2022 | |
| Boston Scientific Corporation | $52.09 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $51.48 | 2021 | |
| Astellas Pharma US INC | $49.28 | 2019-2020 | |
| Amgen INC. | $45.32 | 2019-2020 | |
| Irhythm Technologies, INC. | $29.64 | 2019-2020 | |
| Portola Pharmaceuticals, LLC | $19.57 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $17.52 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $16.80 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.20 | 2019 | |
| Pfizer INC. | $15.57 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shockwave Medical, INC | $14.00 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Devlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.